Clinical Trial

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-18; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2026-02-05
Trial Details
NCT Number NCT07247266
Lead Sponsor Akros Pharma Inc.
Collaborators: PPD Development, LP
Conditions Cryopyrin-associated Periodic Syndromes (CAPS)
Enrollment 5 participants
Start Date 2026-02-02
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-09